We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

The usual suspects

2 July 2010 By Robert Cyran

The French drug maker faces a wall of patent expirations so though the company isn t saying, news that it may shell out for a U.S. biotech to replenish its pipeline makes sense. Among potential targets, Allergan or Genzyme would make a good fit, but Biogen Idec has more warts.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)